GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.

[1]  N. Yamamoto,et al.  Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies , 2007 .

[2]  D. Accili,et al.  Metabolic Diapause in Pancreatic β-Cells Expressing a Gain-of-function Mutant of the Forkhead Protein Foxo1* , 2007, Journal of Biological Chemistry.

[3]  N. Yamamoto,et al.  Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. , 2007, The Journal of endocrinology.

[4]  B. Yusta,et al.  GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress , 2006 .

[5]  D. Accili,et al.  Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic β-Cell Mass , 2006, Diabetes.

[6]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[7]  Sunmin Park,et al.  Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function* , 2006, Journal of Biological Chemistry.

[8]  P. Zimmet,et al.  Introduction: Globalization and the Non‐communicable Disease Epidemic , 2006, Obesity.

[9]  Sunmin Park,et al.  Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. , 2006, The Journal of biological chemistry.

[10]  B. Yusta,et al.  GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. , 2006, Cell metabolism.

[11]  Yazhou Li,et al.  β-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1 , 2005 .

[12]  Yazhou Li,et al.  beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. , 2005, Diabetes.

[13]  S. Bonner-Weir,et al.  Five stages of evolving beta-cell dysfunction during progression to diabetes. , 2004, Diabetes.

[14]  J. Holst,et al.  Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. , 2004, Current opinion in pharmacology.

[15]  J. Holst,et al.  The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. , 2004, Diabetes.

[16]  M. Prentki,et al.  Glucagon-like peptide-1 prevents beta cell glucolipotoxicity , 2004, Diabetologia.

[17]  C. Rhodes,et al.  Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells , 2004, Diabetologia.

[18]  Kathrin Maedler,et al.  Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes , 2003, Journal of Molecular Medicine.

[19]  John Calvin Reed,et al.  cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2 , 2003 .

[20]  R. Perfetti,et al.  Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. , 2003, Endocrinology.

[21]  R. Pederson,et al.  Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats , 2003 .

[22]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[23]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[24]  Xueying Lin,et al.  cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. , 2003, Genes & development.

[25]  M. Prentki,et al.  Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. , 2003, Diabetes.

[26]  R. Pederson,et al.  Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. , 2003, Diabetes.

[27]  Yazhou Li,et al.  Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. , 2003, The Journal of biological chemistry.

[28]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[29]  M. Prentki,et al.  Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor , 2003 .

[30]  Y. Kido,et al.  The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. , 2002, The Journal of clinical investigation.

[31]  R. Perfetti,et al.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. , 2002, Endocrinology.

[32]  J. Holst,et al.  Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. , 2002, European journal of endocrinology.

[33]  P. Brubaker,et al.  Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice , 2002, Diabetologia.

[34]  D. Drucker,et al.  Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. , 2002, Receptors & channels.

[35]  D. Moller,et al.  New drug targets for type 2 diabetes and the metabolic syndrome , 2001, Nature.

[36]  Christophe Benoist,et al.  β-Cell death during progression to diabetes , 2001, Nature.

[37]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[38]  M. Prentki,et al.  Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation , 2001 .

[39]  O. Chepurny,et al.  cAMP‐regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+‐induced Ca2+ release in INS‐1 pancreatic β‐cells , 2001, The Journal of physiology.

[40]  D. Drucker,et al.  Minireview: the glucagon-like peptides. , 2001, Endocrinology.

[41]  M. Prentki,et al.  Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. , 2001, Diabetes.

[42]  C Benoist,et al.  beta-Cell death during progression to diabetes. , 2001, Nature.

[43]  D. Hörsch,et al.  Integrative Mitogenic Role of Protein Kinase B/Akt in β‐Cells , 2000 .

[44]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[45]  D. Hörsch,et al.  Integrative mitogenic role of protein kinase B/Akt in beta-cells. , 2000, Annals of the New York Academy of Sciences.

[46]  M. Prentki,et al.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells , 1999, Diabetologia.

[47]  J. Holst,et al.  Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling , 1998, Diabetes.

[48]  J. Habener,et al.  Activation of a cAMP-regulated Ca-Signaling Pathway in Pancreatic -Cells by the Insulinotropic Hormone Glucagon-like Peptide-1 (*) , 1995, The Journal of Biological Chemistry.

[49]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[50]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[51]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[52]  B. Thorens.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[54]  J. Habener,et al.  Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. , 1992, Endocrinology.

[55]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.